AMERISOURCEBERGEN
17.11.2022 14:31:38 CET | Business Wire | Press release
Alliance Healthcare, a part of global healthcare company AmerisourceBergen and a leading wholesaler of pharmaceutical products in Europe, and GIRP, the European Healthcare Distribution Association, convened policymakers and leaders across the healthcare and pharmaceutical industries today to discuss antimicrobial resistance (AMR), examine current response efforts and explore opportunities to collaborate on initiatives to combat the global public health issue.
The inaugural event featured remarks from members of the European Parliament, European Commission and organizations spearheading AMR response efforts, as well as panel discussions led by healthcare and pharmaceutical executives. Panelists and speakers covered a variety of topics, including how public policy can advance response efforts, strategies to increase awareness of AMR, actions healthcare providers are taking to combat resistance, and public-private partnerships to support the development of new antimicrobials. Professor Dame Sally Davies, UK Special Envoy on AMR and member of the UN Global Leaders Group on AMR, delivered a keynote address focused on mobilizing international efforts and driving a global response.
AMR, which occurs when a microorganism (bacteria, virus, fungi, parasite) develops the ability to resist the effects of a drug, is a significant global public health threat. The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR.
“Addressing an issue as complex and far-reaching as AMR requires public-private collaboration and coordination across multiple sectors,” said Gianluigi Tassone, President of Alliance Healthcare. “By hosting this event, we sought to bring together policymakers, leaders across the healthcare supply chain and those at the forefront of international response efforts to discuss current approaches, share best practices and identify opportunities in which we can work together to help address this issue.”
“As the EU outlined in its action plan, there is an urgent need for multi-sector collaboration, innovation and policy action to tackle AMR,” said Monika Derecque-Pois, Director General of GIRP. “While this event serves as an important step in bringing together leaders across different industries, it’s equally important we continue these conversations and build on the potential solutions discussed today to help drive meaningful, sustained change.”
During the provider-focused panel, leaders from the European Hospital and Healthcare Federation, Standing Committee of European Doctors, European Association of Hospital Pharmacists and Boots UK offered perspective on how healthcare systems across Europe are prepared to manage AMR. The panelists spoke to the actions needed to combat resistance, including infection prevention and control measures, and initiatives underway to educate patients on AMR. For example, Alphega Pharmacy, a pan-European network of independent pharmacists and a part of Alliance Healthcare, launched a campaign to drive awareness of AMR and provide patients with additional counseling and education on proper use of antibiotics.
Representatives from the AMR Action Fund, a public-private partnership investing in biotech companies that are developing antibiotics, and BEAM Alliance, a coalition of small and medium-sized biopharma companies in Europe involved in developing products to combat AMR, discussed current industry priorities, including innovative approaches to support the research and development of new antibiotics and sustainable models to improve access to new antibiotics, diagnostics and vaccines globally.
“AMR is a silent pandemic. No one player can solve it on their own – it demands a coordinated approach,” said Dame Sally. “By collaborating across sectors and countries, we can innovate to secure the future of modern medicine so that treatments can be used sustainably by all who need them.”
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our more than 43,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at https://amerisourcebergen.com/.
European Healthcare Distribution Association (GIRP)
GIRP, the European Healthcare Distribution Association, is the umbrella organisation for full-service healthcare distributors in Europe. It represents the national associations of over 750 pharmaceutical wholesalers serving 34 European countries, as well as major international and pan-European healthcare distribution companies. GIRP members employ over 140,000 people and distribute around 15 billion packs of medicines as well as a wide range of healthcare products per year. As the vital link in healthcare, they are committed to developing and providing innovative and efficient healthcare products and services to improve health and wellbeing of patients across Europe. Learn more at girp.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005239/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
Grid Dynamics Enters Strategic Partnership with Doosan Robotics to Accelerate Physical AI Adoption Across Manufacturing and Logistics16.7.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics partners with Doosan Robotics to provide industrial cobot users with a turnkey software stack for physical AI and corresponding integration services. Grid Dynamics offerings enable Doosan cobot users to solve advanced robotic automation use cases such as processing and inspection of complex-geometry objects, assembly with variability, and packaging of unseen and deformable items. This partnership positions Grid Dynamics to address the fast-growing physical AI market with applied end-to-end solutions including foundational AI components, software platforms, integration services, and hardware for a broad range of manufacturing and logistics companies. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, announced today it has entered into a strategic partnership with Doosan Robotics, a global leader in collaborative robot solutions, delivering cutting-edge AI robotics to 45 countries worldwide.
NetApp Acquires DataPelago, Making Data AI-Ready at the Infrastructure Layer16.7.2026 18:30:00 CEST | Press release
Embedding GPU-accelerated intelligence enables enterprises to easily discover, govern, and activate data for AI and analytics at the source NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has acquired DataPelago, a California-based AI data infrastructure company recognized for its innovative approach to eliminating data processing bottlenecks for AI and analytics workloads. The acquisition marks a foundational expansion of NetApp's portfolio, enabling GPU-accelerated data processing aligned directly with the storage layer. With this acquisition, NetApp establishes itself as the company that makes zero-copy activation of enterprise data for AI real. AI is the defining platform shift of our era, but enterprises are discovering that their greatest bottleneck is preparing, governing, and activating their data fast enough to put AI into production. The key to accomplishing this objective is to enable accelerated computing where the data is created and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom